Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Chaekal O-, Scaradavou A, Frenet EM, Albano MS, Cushing M, Desai P, et al. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Adv. 2020;4(20):5146-5156.

Zhong E, Solomon JP, Cheng E, Baum J, Song W, Hoda SA. Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ: Further Clinical, Histopathologic, Immunohistochemical, and Molecular Characterization of an Emerging Entity. Am J Surg Pathol. 2020;44(8):1092-1103.

Rendeiro AF, Ravichandran H, Bram Y, Salvatore S, Borczuk A, Elemento O, et al. The spatio-temporal landscape of lung pathology in SARS-CoV-2 infection. medRxiv. 2020.

Sanchez AM, Garg A, Shuman S, Schwer B. Genetic interactions and transcriptomics implicate fission yeast CTD prolyl isomerase Pin1 as an agent of RNA 3' processing and transcription termination that functions via its effects on CTD phosphatase Ssu72. Nucleic Acids Res. 2020;48(9):4811-4826.

Vickman RE, Faget DV, Beachy P, Beebe D, Bhowmick NA, Cukierman E, et al. Deconstructing tumor heterogeneity: the stromal perspective. Oncotarget. 2020;11(40):3621-3632.

Rubinstein MM, Goss C, Avecilla ST, Dubé GP, Riely GJ, Mones JV. Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness. Clin Case Rep. 2020;8(2):289-292.

Strother RM, Gopal S, Wirth M, Chadburn A, Noy A, Cesarman E, et al. Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 Study. JCO Glob Oncol. 2020;6:1034-1040.

Kalish JM, Tang X-, Scognamiglio T, Zhang T, Gudas LJ. Doxycycline-induced exogenous Bmi-1 expression enhances tumor formation in a murine model of oral squamous cell carcinoma. Cancer Biol Ther. 2020;21(5):400-411.

Solomon JP, Arcila ME. Molecular Diagnostics of Non-Hodgkin Lymphoma. Cancer J. 2020;26(3):186-194.

Allott EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, Markt SC, Wilson KM, et al. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020;26(5):1086-1093.